Navigation Links
Global Access Project (GAP) Study Examining Patients' Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA)
Date:7/9/2008

e Duke researchers studied data about Medicare beneficiaries who received chemotherapy for diagnoses of leukemia, lymphoma, breast, lung or colorectal cancer from across the United States. They looked at the distance patients traveled to get their chemotherapy treatments, and the amount of time that lapsed from diagnosis to initiation of chemotherapy. They compared data from 2003, before the MMA took effect, to the data from subsequent years through 2006. They did not examine other quality of care indicators.

When the MMA was signed into law by President Bush in 2003, it was the most comprehensive restructuring of Medicare since its inception in 1965. The law created a prescription drug benefit and provided $25 billion for rural hospitals, but it also significantly reduced Medicare reimbursements to healthcare providers starting January 1, 2005. Cancer care, in particular, was targeted for cuts because legislators considered it to have been overly funded.

"We strive to help cancer patients access convenient, safe and high-quality care -- no matter where they live or what their insurance issues may be," said Davenport-Ennis. "Though the JAMA study overall did not find that cancer patients are being negatively impacted as a result of the MMA, its suggestion of longer wait times for patients in rural areas should be researched further so that we can learn more about the situations these patients are facing -- and, in turn, learn how to best overcome them."

National Patient Advocate Foundation (NPAF) is a national, non-profit organization that is dedicated to the mission of creating avenues of patient access through improved access to, and reimbursement for, evolving therapies, therapeutic agent, and devices through policy and legislative reform at the state and federal levels. Our mission is shaped by the experiences of the patients served through our companion organization, Patient Advocate Foundation.


'/>"/>
SOURCE National Patient Advocate Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases
2. Global Med Technologies(R) Announces U.S. Release of Proven Tissue and Cellular Therapy Product
3. Proposing a New Global Compact for Infectious Diseases
4. The Center for Professional Innovation and Education (CfPIE) Announces a New Global Regulatory Certification Track
5. GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems
6. Signalife and Heart One Global Research Agree to Merge
7. AEGON and Right To Play Announce Global Partnership
8. MED3OOO and Mitsui & Co. Complete U.S. and Global Healthcare Partnership Agreement
9. National Press Club to Host NEWSMAKER Media Briefing on Global Health and the Infections of Poverty - Neglected Tropical Diseases
10. Chronic Kidney Disease Growing Globally
11. TechTeam Global Announces Formation of a Global Pharmaceutical Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
... boy from Indonesia had a tumor measuring about 7....or made up around 10% of his body weight.// The tu...ingapore at Mount Elizabeth Hospital involving dif...eloped due to an Iodine deficiency which is an end...
... Brian Jago, from the UK has said that he is being...lable in Wales and Scotland.// Jago has been diagn...n July 2003. He has undergone a stem cell transpla...iled to check the disease. The Southampton Univer...
...nges the one accepted truism of dietary research s...inst colorectal cancer.// The latest analysis of ...od with high fibre content such as cereals, vegeta...to get colon cancer, fiber-cancer association is w...
... the progression of chronic myelogenous leukemia (...ientists. They have also found out that an extract...is called forskolin can be used for suppressing th...e are expected to develop CML this year, and the f...
Other Medicine News:Health News:Study finds no link between fibre and cancer risk 2
(Date:8/25/2008)...lls Found in Menstrual Blood May Offer Long-Lastin...ed Women, OLDSMAR, Fla., Aug. 25 /- ...ould agree that there never seems to be enough,of ... doing something just,for herself usually pales in...s reality has led many women in need of quality ti...
(Date:8/25/2008)...s., Aug. 25 /- Joseph F. Finn, Jr.,C..., Inc. ("Spherics") for,the benefit of creditors, ...al property will be sold at a sealed bid auction o...se formulation of Levodopa-Carbidopa that,is the c...ease, with global,sales estimated at approximately...
(Date:8/25/2008)...ug. 25 /- Anthera Pharmaceuticals,Inc...loping,anti-inflammatory drugs, today announced th... coronary events with Near-term Cardiovascular,Inf...examine the impact of,varespladib when administere... Syndrome (ACS) event., The FRANCIS trial is desi...
(Date:8/22/2008)... in Trial Sponsored by Medical Research Council, ...- Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) a...tocol MDP 301, a Phase III clinical trial of PRO 2...or the prevention of HIV and other,sexually transm...ited,Kingdom,s Medical Research Council (MRC) and ...
Breaking Medicine Technology:Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 2Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 4Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 5Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 1Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 1Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 2Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 4Heart Attack Survivors Benefit From Rehab 2063 1Heart Attack Survivors Benefit From Rehab 2063 2Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 568 1Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 568 2
... Researchers at,Molecular Insight Pharmaceuticals ...ta on MIP-1072, a radiolabeled, small molecule,mol...iagnosis and,staging of prostate cancer at the 54t...e (SNM) in Washington, D.C. MIP-1072 is,one of two...sis,that Molecular Insight plans to advance into e...
...Corporation,(NASDAQ: CYTO) today reported results ...(samarium Sm-153 lexidronam injection),can be safe...e also,receiving the chemotherapy docetaxel (Taxot...t further evaluation of the combination,regimen fo...ogram.,The results were presented and/or published...
Other Medicine Technology:Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7
...ons about insulin dosages and other medication, ab...ed by data from blood glucose tests and other rele...seen by you and your Health Care Providers when th...mats. The FreeStyle CoPilot System makes the data ...
... Photocoagulator.,Retinal physicians throughout ...is multi-color photocoagulators.,For the retinal...integrates green, yellow, and red solid-state,d...hat supports your treatment of a diverse range of ...
... Photocoagulator.,Retinal physicians throughout ...is multi-color photocoagulators.,For the retinal...integrates green, yellow, and red solid-state,d...hat supports your treatment of a diverse range of ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction.
Medicine Products: